[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility-ivf-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility-ivf-patients":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,54,89,120,151,175,202,230,251,271,300,325,375,405,439,467,498,522,547,571,599,625,658,680,702],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100588405","study-of-abnormally-fertilized-embryos-100588405",false,"NCT06940973","Study of Abnormally Fertilized Embryos","Prospective Observational Study of the Morphokinetics and Ploidy of Blastocysts With Abnormal Fertilization (1PN, 2.1PN and 3PN) to Identify the Origin of Fertilization Alterations","SAFE","Inclusion Criteria:\n\n* ART patients who sign the Informed Consent of the study.\n* Age: oocytes from women ≤ 49 years and semen from men ≤ 60 years. Donation of gametes is allowed.\n* ≥1 blastocysts from oocytes with an abnormal pronuclear pattern (1PN, 2.1PN, and\u002For 3PN) and with the presence of 2 polar bodies (PB), cultured in a time-lapse incubator.\n\nExclusion Criteria:\n\n* No exclusion criteria have been considered for this study.","ALL","18 Years","49 Years",{"count":22,"type":23},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the diploidy rate of haploid and triploid embryos from in vitro fertilization (IVF) cycles. The main questions it aims to answer are:\n\n* Can a molecular genetic fertilization check of abnormally fertilized embryos be used to expand opportunities for couples undergoing assisted reproduction treatment?\n* Is the chromosomal loss or gain present in abnormally fertilized embryos predominantly maternal in origin?\n\nFor this purpose, we will evaluate the morphokinetics and ploidy of about 300 embryos with different types of abnormal pronuclear patterns (1PN, 2.1PN, and 3PN) that reach the blastocyst stage. Whenever possible, embryos with a non-diploid chromosomal complement will also be assessed to determine the origin (maternal or paternal) of the chromosomal set that has been lost or gained.\n\nStudy subjects will follow their previously scheduIed IVF\u002FICSI treatment and no additional visits\u002Finterventions will be required for participating.",[27],"Infertility (IVF Patients)",[29,30,31,32,33,34,35,36,37,38,39,40],"PGT-A","niPGT-A","Blastocyst","Infertility","In vitro fertilization","Ploidy","Embryo development","Time-lapse culture","Triploid","Haploid","Abnormal fertilization","Pronuclei","RECRUITING","2026-08-20",{"date":44,"type":45},"2026-08-21","ACTUAL",{"date":47,"type":45},"2025-07-02",{"date":49,"type":23},"2026-09",{"name":51,"class":52},"Igenomix","INDUSTRY",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":53},"100652396","225-iu-versus-300-iu-starting-fsh-dose-in-ppos-for-good-prognosis-women-100652396","NCT07772375","225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women","A Randomized Controlled Trial Comparing 225 IU Versus 300 IU Starting Doses of Follicle-Stimulating Hormone in Progestin-Primed Ovarian Stimulation for Women With Good Prognosis","FSH-PPOS","Inclusion Criteria:\n\n* Female patient or oocyte donor aged \\\u003C35 years.\n* Body mass index (BMI) between 18 and 25 kg\u002Fm².\n* Normal ovarian reserve, defined by:\n\n  * Antral follicle count (AFC) ≥8 on ultrasound; and\n  * AMH level between 1.5 and 4.5 ng\u002FmL.\n* First IVF treatment cycle.\n* Controlled ovarian stimulation using a progestin-primed ovarian stimulation (PPOS) protocol with recombinant FSH and dydrogesterone.\n* Indication for in vitro fertilization using intracytoplasmic sperm injection (ICSI).\n* Indication for extended embryo culture to the blastocyst stage.\n* Willingness to participate in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n* Polycystic ovary syndrome (PCOS) diagnosed according to the Rotterdam criteria, currently referred to as polyendocrine metabolic ovarian syndrome (PMOS).\n* Structural abnormalities of the ovaries.\n* Ovarian endometriosis.\n* Medical or gynecological conditions that may affect ovarian response to controlled ovarian stimulation.\n* Indication for luteinizing hormone (LH) supplementation during controlled ovarian stimulation.\n* Poor sperm quality, cryptozoospermia, surgically retrieved sperm (PESA, TESE, or microTESE), cryopreserved sperm, or donor sperm.\n* Indication for artificial oocyte activation (AOA) or rescue ICSI (R-ICSI).","FEMALE","34 Years",{"count":65,"type":23},380,"INTERVENTIONAL",[68],"NA","This randomized controlled trial will compare two starting doses of follicle-stimulating hormone (FSH), 225 IU and 300 IU, during progestin-primed ovarian stimulation (PPOS) in women undergoing in vitro fertilization (IVF) who have a good reproductive prognosis. Participants will be randomly assigned to receive either 225 IU or 300 IU of FSH at the start of ovarian stimulation. The study will evaluate whether the starting FSH dose affects oocyte and embryo outcomes, with blastocyst formation as the primary outcome. Other outcomes will include oocyte morphology, fertilization, embryo development, and embryo quality. The findings may help determine an appropriate starting FSH dose for women with a good prognosis undergoing IVF using the PPOS protocol.",[27,71],"Infertility Assisted Reproductive Technology",[73,74,75,76,77],"Progestin-primed ovarian stimulation","PPOS","FSH dose","Embryo quality","blastulation","NOT_YET_RECRUITING","2026-08-17",{"date":81,"type":45},"2026-08-19",{"date":83,"type":23},"2026-08-15",{"date":85,"type":23},"2029-08-31",{"name":87,"class":88},"Vietnam Military Medical University","OTHER",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":62,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":66,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100652143","rct-study-on-the-effect-of-etn-on-live-birth-rate-in-dor-patients-undergoing-ivf-et-100652143","NCT07769684","RCT Study on the Effect of ETN on Live Birth Rate in DOR Patients Undergoing IVF-ET","Effect of Electro-thumbtack Needle (ETN) on Live Birth Rate in Patients With Diminished Ovarian Reserve (DOR) Undergoing IVF-ET: A Multicenter Randomized Controlled Clinical Trial","ETN-LBR-DOR","Inclusion Criteria:\n\n* 1\\. Age between 20-42 years old;\n* 2\\. Meet the DOR diagnostic criteria: Diagnosis of diminished ovarian reserve (DOR) can be made if any two of the following three criteria are met: ①Serum AMH level ≤ 1.1 ng\u002FmL; ②On days 2-4 of the menstrual cycle, transvaginal ultrasound demonstrates a total number of basal antral follicles (diameter 2-10 mm) in both ovaries \\\u003C7 (antral follicle counting, AFC); ③For two consecutive menstrual cycles, on days 2-4, serum FSH levels range from 10 U\u002FL to \\\u003C25 U\u002FL.\n* 3\\. Semen routine examination of the participant's spouse is normal: sperm concentration ≥15×10⁶\u002FmL, proportion of forward-moving sperm ≥32%, proportion of normally shaped sperm ≥4%;\n* 4\\. Intend to undergo In Vitro Fertilization - Embryo Transfer (IVF-ET);\n* 5\\. Voluntarily participate in this study, sign the informed consent form, and be able to cooperate to complete the treatment and follow-up.\n\nExclusion Criteria:\n\n* 1\\. Chromosomal or genetic abnormalities in the female or male partner;\n* 2\\. History of ovarian surgery, such as surgery for ovarian teratomas or ovarian chocolate cysts;\n* 3\\. Uterine abnormalities that may affect embryo implantation (including uterine malformations, uterine tuberculosis, adenomyosis, and submucosal myomas \\>4 cm);\n* 4\\. Unresolved intrauterine adhesions, endometritis, or endometrial polyps;\n* 5\\. The female partner has uncorrected endocrine disorders such as uncomplicated hyperthyroidism or hypothyroidism, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, or has taken antipsychotic medications in the past 3 months;\n* 6\\. The female partner has a confirmed diagnosis of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Sjögren's syndrome, or Hashimoto's thyroiditis;\n* 7\\. Three or more failed embryo transfers;\n* 8\\. History of malignant tumors in the female or male partner with prior radiotherapy or chemotherapy;\n* 9\\. The female partner has received acupuncture or press needle therapy in the past 3 months;\n* 10\\. Use of Chinese herbal decoctions or granules during treatment;\n* 11\\. Abnormal semen analysis in the male partner;\n* 12\\. Refusal to undergo in vitro fertilization - embryo transfer (IVF-ET);\n* 13\\. Refusal to sign the informed consent form for this study.","20 Years","42 Years",{"count":100,"type":23},406,[68],"The goal of this clinical trial is to examine the effect of ETN on live birth rate in patients with diminished ovarian reserve (DOR) undergoing in vitro fertilizitaion-embryo transfer (IVF-ET). Four hundred and six patients with DOR will be enrolled randomly divided into treatment group and control group, with 203 patients in each group. The treatment group will receive electro-thumbtack needle (ETN) therapy, while the control group received placebo ETN. Both groups initiated treatment 1 to 3 menstrual cycles before IVF-ET and continued until the intramuscular injection of HCG (night injection) during the IVF cycle. The study will observe and compare the pregnancy outcomes (including live birth rate, clinical pregnancy rate, biochemical pregnancy rate, threatened abortion, abortion, oocyte retrieval, and embryo quality), ovarian reserve function, anxiety, depression, sleep status, and quality of life between the two groups.",[104,27],"Diminished Ovarian Reserve (DOR)",[106,107,108,109],"Diminished ovarian reserve","IVF-ET","Live birth rate","Electro-thumbtack needle","2026-08-12",{"date":112,"type":45},"2026-08-18",{"date":114,"type":23},"2026-08-01",{"date":116,"type":23},"2031-12-31",{"name":118,"class":88},"Huazhong University of Science and Technology",4,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":74,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":62,"minAge":97,"maxAge":98,"enrollmentInfo":127,"targetDuration":4,"studyType":66,"phases":129,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":53},"100649613","phase-1-drospirenone-primed-ovarian-stimulation-versus-gnrh-antagonist-protocol-in-poor-ovarian-responders-undergoing-freeze-all-ivficsi-100649613","NCT07736261","Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF\u002FICSI","Drospirenone-Primed Ovarian Stimulation (PPOS) Versus Flexible GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing a Freeze-All Strategy: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Spontaneous menstrual cycles (21-35 days)\n* Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC \\\u003C7 or AMH \\\u003C1.1 ng\u002FmL)\n* POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes\n* Indication for IVF\u002FICSI\n* Willing and able to undergo mandatory freeze-all\u002FFET protocol\n* Signed informed consent, including explicit acknowledgment that fresh transfer is not offered in either study arm\n\nExclusion Criteria:\n\n* Contraindication to ovarian stimulation\n* Known müllerian anomaly\n* Uncontrolled systemic disease\n* 5 prior failed IVF attempts\n* Known contraindication to drospirenone (per product labeling, e.g., renal impairment, adrenal insufficiency, conditions predisposing to hyperkalemia)",{"count":128,"type":23},100,[130,131],"PHASE1","PHASE2","Participants will:\n\n* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections\n* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)\n* Have a frozen embryo transferred in a later cycle\n* Complete two short questionnaires about their treatment experience - once before starting the injections\u002Fpills, and once after the stimulation phase ends\n* Be followed to determine if the embryo transfer results in a pregnancy",[134,27],"Poor Ovarian Reserve",[136,137,138,139,140,141],"poor ovarian response","diminished ovarian reserve","Drospirenone","progestin primed ovarian stimulation","GnRH antagonist","Freeze all","2026-07-29",{"date":144,"type":45},"2026-07-30",{"date":146,"type":23},"2026-08",{"date":148,"type":23},"2027-11",{"name":150,"class":88},"Ahmed Saad",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":62,"minAge":19,"maxAge":63,"enrollmentInfo":158,"targetDuration":160,"studyType":24,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":173,"locationsCount":53},"100645453","correlation-of-clinical-outcomes-after-transfer-of-good-quality-morphology-embryos-in-patients-with-a-favorable-prognosis-and-non-invasive-preimplantation-genetic-testing-for-aneuploidy-nipgt-a-results-100645453","NCT07700602","Correlation Of Clinical Outcomes After Transfer Of Good-Quality Morphology Embryos In Patients With A Favorable Prognosis And Non-Invasive Preimplantation Genetic Testing For Aneuploidy (NiPGT-A) Results","Inclusion Criteria:\n\n* Women undergoing in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI).\n* Age younger than 35 years at the time of oocyte retrieval.\n* Good ovarian response, defined as having at least four good-quality embryos (Grade 1 or Grade 2) on Day 3 or later.\n* Undergoing the first or second IVF cycle.\n* Normal semen parameters of the male partner.\n* Willing to undergo non-invasive preimplantation genetic testing for aneuploidy (NiPGT-A) using spent embryo culture media.\n* Agree to vitrification of a single morphologically best-quality blastocyst and to undergo frozen single embryo transfer.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of untreated uterine abnormalities, including uterine malformations or significant intrauterine pathology.\n* History of uterine surgery.\n* History of ovarian surgery.\n* Known metabolic disorders.\n* Use of donor oocytes.\n* In vitro maturation (IVM) cycles.\n* Participation in another clinical study during the study period.\n* Patients who do not undergo frozen single embryo transfer.",true,{"count":159,"type":23},200,"24 Months","Non-invasive preimplantation genetic testing for aneuploidy (NiPGT-A) is an emerging approach that analyzes embryonic cell-free DNA (cfDNA) released into the spent culture medium (SCM) to assess chromosomal status without performing trophectoderm biopsy. This technique has the potential to reduce procedural invasiveness and eliminate biopsy-related risks while providing additional information for embryo selection in assisted reproductive technology (ART). However, the clinical value of NiPGT-A remains uncertain because available evidence is limited and largely derived from observational studies, with few studies reporting live birth outcomes.\n\nThis prospective observational study aims to evaluate the correlation between NiPGT-A results and clinical outcomes after single blastocyst transfer in patients with a favorable prognosis undergoing IVF\u002FICSI treatment. In this study, embryos with good morphological quality will undergo non-invasive sampling of spent culture medium for cfDNA analysis. NiPGT-A results will be categorized into four groups: no result, euploid, mosaic, and aneuploid. The study will compare pregnancy and birth outcomes across these groups to determine the clinical utility of NiPGT-A in embryo selection strategies.",[27,163,164],"Clinical Pregnancy After Single Embryo Transfer","Embryo Diagnosis and Selection",[166],"NiPGT, IVF, morphology, embryo selection","2026-07-13",{"date":169,"type":45},"2026-07-14",{"date":114,"type":23},{"date":172,"type":23},"2029-12-31",{"name":174,"class":88},"Mỹ Đức Hospital",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100628035","development-of-an-ai-platform-for-the-analysis-of-sperm-and-prediction-of-their-clinical-potential-100628035","NCT07456397","Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential","Development and Validation of an Artificial Intelligence Platform for the Analysis of Sperm Samples and Prediction of Their Clinical Potential","Spermy01","Male participants:\n\nInclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n* Semen sample intended for use in an IVF\u002FICSI cycle\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months\n\nFemale participants:\n\nInclusion Criteria:\n\n* Urdengoing an IVF\u002FICSI cycle with partner or donor semen\n\nExclusion Criteria:\n\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","60 Years",{"count":185,"type":23},500,"Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to develop an artificial intelligence platform for the analysis of sperm samples and prediction of their clinical potential, in 500 semen samples, in an in vitro study over 24 months.",[27,188,189,190,191],"ICSI","IVF Outcomes","Male Infertility","Reproductive Issues","2026-06-10",{"date":194,"type":45},"2026-06-12",{"date":196,"type":45},"2026-03-18",{"date":198,"type":23},"2028-02",{"name":200,"class":88},"Fecundis Lab SL",5,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":66,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":53},"100643177","a-large-scale-prospective-cohort-study-was-conducted-to-explore-the-association-between-environmental-exposure-and-behavioral-factors-and-infertility-the-success-rate-of-assisted-reproductive-technology-100643177","NCT07641387","A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)","Inclusion Criteria:\n\n* 1\\. Women aged 18 to 46 who use their own eggs or men aged 18 to 55 who use their own sperm; 2. Patients who meet the diagnostic criteria for infertility; 3. Clarify the medical history of persistent infertility for a certain period of time; 4. Voluntarily participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Artificial insemination population with any of the following ARTs contraindications: a. Impairment of sperm and egg combination caused by fallopian tube factors on the female side. b. The female side suffers from acute infection of the reproductive and urinary system or sexually transmitted diseases. c. The female side suffers from genetic diseases, serious physical diseases, and mental and psychological disorders. d. There is a history of birth of babies with congenital defects and it is confirmed that it is caused by female factors. e. The female side is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. f. The female side has bad habits such as alcoholism and drug abuse.\n\n  2\\. First-generation test-tube baby and second-generation test-tube baby population with any of the following ARTs contraindications: a. Any party who provides gametes suffers from acute infection of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism and drug abuse. b. Any party who provides gametes is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. c. The couple who received embryo donation\u002Fegg donation suffers from acute infection of reproductive and urinary system and sexually transmitted diseases, or has bad habits such as alcoholism and drug abuse. d. The woman's uterus is not capable of pregnancy or has a serious physical disease that cannot withstand pregnancy.\n\n  3\\. No embryo transfer after egg retrieval; 4. Frozen embryo transfer is received more than 180 days after egg retrieval.","55 Years",{"count":210,"type":23},5000,[68],"The aim is to explore the reasons for the failure of assisted reproductive technology (ART) in infertile patients in Hunan Province and seek ways to improve the success rate of ART. The study will focus on how environmental exposure (such as environmental pollutants related to plastic products) and lifestyle and social factors affect the success rate of ART in infertile patients.\n\nIn order to explore these issues in depth, the study plans to collect 5,000 samples (male: female ratio 1:1), screen the research subjects from infertile patients who visited Xiangya Third Hospital in Changsha, Hunan Province, and establish a large-scale, prospective infertility patient cohort. By collecting multi-faceted information of the research subjects, including sociodemographic characteristics, lifestyle, basic health status, etc., and conducting long-term follow-up observations, the ART live birth situation of infertile patients is analyzed.\n\nIn terms of research methods, a multivariate analysis method will be used to explore the association between various factors and ART success rate, and a risk prediction model will be constructed. In addition, the study also hopes to clarify the specific reasons for the failure of infertile patients to receive ART, provide a scientific basis for clinical decision-making, and provide guidance for the formulation of environmental protection policies and the improvement of public reproductive health literacy.\n\nIn general, this study, through a large-scale, prospective cohort study, deeply explores the various factors that affect the success rate of ART in infertile patients, and strives to build a risk prediction model in order to improve the success rate of ART and bring more hope to infertile families.",[32,71,27],[215,216,217,218,219,220],"environmental pollutants","Assisted Reproductive Technology","prospective cohort","life-style","risk factor","social factor","2026-06-08",{"date":223,"type":45},"2026-06-11",{"date":225,"type":45},"2025-04-01",{"date":227,"type":23},"2035-04-01",{"name":229,"class":88},"The Third Xiangya Hospital of Central South University",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":237,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":53},"100583744","male-infertility-and-assisted-reproductive-technologies-research-biobank-100583744","NCT06880302","Male Infertility and Assisted Reproductive Technologies Research Biobank","MARK","Inclusion Criteria:\n\n* Males providing testicular tissue, sperm, semen samples, discarded sperm preps for IUI\u002FIVF\u002FICSI or the sperm recipient for those utilizing donor sperm, for cryopreservation at the respective site(s) for either clinical use or preservation\n\nExclusion Criteria:\n\n* Samples that are quarantined or in isolation dewars for infectious diseases","MALE",{"count":239,"type":23},1000,"The objective of this research is to build a biobank of biological male specimens used for diagnostics and treatment of infertility or assisted reproductive technologies (ART).",[190,27],"2026-06-01",{"date":244,"type":45},"2026-06-02",{"date":246,"type":45},"2025-03-04",{"date":248,"type":23},"2032-12",{"name":250,"class":88},"Reproductive Medicine Associates of New Jersey",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":157,"sex":62,"minAge":19,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":53},"100578829","quantifying-uterine-elastography-in-menstruating-women-100578829","NCT06816381","Quantifying Uterine Elastography in Menstruating Women","Characterizing Uterine and Ovarian Tissue Stiffness Via Shear Wave Elastography in Non-Infertile, Fertile, and Infertile Women With Normal Anatomy Across the Menstrual Cycle: A Pilot Study","QUEST","Group A\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28-34 days\n* Patients with normal uterine anatomy\n* Patients with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries\n* Patient who have no known infertility (i.e. women who have not tried to conceive)\n\nExclusion Criteria:\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of -endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup B\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patients with at least one prior full-term vaginal delivery with time to conception less than one year without the use of assisted reproductive technology.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of cesarean section\n* Patient who have no known secondary infertility (i.e. women who have not tried to conceive)\n* Diagnosis of secondary infertility (i.e women who have attempted pregnancy for 12 months without success)\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup C\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patient with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries (i.e gravity equals zero).\n* Patient with diagnosis of primary infertility, with attempted conception for at least 12 months if younger than 35 years and attempted conception for at least 6 months if 35 years or older.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of three or more failed euploid embryo transfers\n* Severe male factor infertility including severe oligozoospermia and cryptozoospermia\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.","45 Years",{"count":261,"type":23},40,"This study is aiming to characterize the elasticity of the female reproductive tract including the uterus, cervix and ovary using shear wave elastography at different times during the menstrual cycle and define the standard reference range of normal uterine and ovarian elasticity. By doing so, the potential of using shear wave elastography to diagnose and predict outcomes for patients seeking fertility treatment might be established.",[27,71],{"date":265,"type":45},"2026-06-03",{"date":267,"type":45},"2025-02-06",{"date":269,"type":23},"2027-12",{"name":250,"class":88},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":66,"phases":280,"briefSummary":281,"conditions":282,"keywords":287,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":53},"100564483","the-epic-study-exploring-paternal-age-and-the-influence-on-blastocyst-culture-100564483","NCT06629766","The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture","EPIC","Inclusion Criteria:\n\n* Undergoing first IVF cycle\n* Electing single embryo transfer\n* Electing PGT-A of their embryos\n* Female partners age \\\u003C42 years old at start of VOR cycle, but \\>18 years old.\n* AMH ≥ 1.2 ng\u002FmL\n* AFC ≥ 8\n* FSH ≤ 12IU\u002FL\n* At least 4 mature oocytes (M2s) retrieved at the VOR procedure in order to randomize\n* Intention to transfer the morphological best quality, euploid, embryo at the frozen embryo transfer procedure\n\nExclusion Criteria:\n\n* Contraindication to IVF\n* Clinical indication for preimplantation genetic testing (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring a more detailed embryo genetic analysis)\n* Male partner with azoospermia or oligozoospermia (\\\u003C500,000 total motile spermatozoa on the most recent semen analysis within one year of enrollment)\n* Planned for previously cryopreserved sperm to be used for ICSI\n* Donor sperm\n* Male partner with Y-chromosome microdeletion\n* Male partner with any Karyotype other than 46,XY\n* Male partner requiring surgically obtained sperm either via testicular or epididymal retrieval procedures\n* Uncorrected hydrosalpinges that communicate with the endometrial cavity\n* Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \\\u003C6mm,), or persistent endometrial fluid\n* Donor oocyte or embryo cycles\n* Gestational carriers","41 Years",{"count":128,"type":23},[68],"This study aims to assess the effect of age of the male partner and the reproductive ability of sperm prepared via sperm selection devices (Zymot) compared to routine embryologist selected sperm after density gradient centrifugation (DGC) preparation for intracytoplasmic sperm injection (ICSI) in patients undergoing in vitro fertilization treatment (IVF) of their infertility.",[27,283,284,285,286],"Oocyte Competence","Sperm DNA Fragmentation","Paternal Age","Sperm Selection",[288,289,290,291,292,293],"microfluidic","density grade centrifugation","sperm selection","paternal age","sperm DNA fragmentation","Zymot",{"date":265,"type":45},{"date":296,"type":45},"2025-04-09",{"date":298,"type":23},"2028-12",{"name":250,"class":88},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":66,"phases":310,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":53},"100636716","phase-2-triggering-ovulation-in-normo-responders-using-a-modified-dual-trigger-protocol-or-hcg-trigger-100636716","NCT07569302","Triggering Ovulation in Normo-responders Using a Modified Dual Trigger Protocol or HCG Trigger","Triggering Ovulation in Normo-responders Using a Modified Dual Trigger Protocol or HCG Trigger . A Randomized Controlled Study","Inclusion Criteria:\n\n* GnRH antagonist IVF cycle\n* Normo-responders to induction of ovulation\n\nExclusion Criteria:\n\n* Hypogonadotrophic hypogonadism\n* Endometriosis\n* History of recurrent abortion","40 Years",{"count":309,"type":23},196,[131],"The aim of this randomized controlled study is to compare the efficacy of a modified dual trigger protocol \\[a single bolos of HCG combined with two successive doses of a GnRH agonist \\] with HCG \\[a single bolos administered 36 hours before oocyte retrieval \\] in triggering ovulation in normo-responders undergoing ovarian stimulation using the antagonist protocol.",[27],[32,107,314,315,316],"Normo-responders","GnRH agonist","HCG","2026-04-29",{"date":319,"type":45},"2026-05-06",{"date":242,"type":23},{"date":322,"type":23},"2028-04-01",{"name":324,"class":88},"Bedaya Hospital",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":62,"minAge":333,"maxAge":98,"enrollmentInfo":334,"targetDuration":4,"studyType":66,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":53},"100624079","biological-aging-hallmarks-guided-integrative-tcm-and-conventional-medicine-in-post-treatment-unexplained-female-infertility-100624079","NCT07404969","Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility","An Interventional Study Evaluating Telomere and Biological Aging Hallmarks Profiling to Guide an Integrative Traditional Chinese and Conventional Medicine Approach in Women With Post-Treatment Unexplained Infertility","TECMI","Inclusion Criteria:\n\n* Biological female participants aged 25 to 42 years.\n* Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and\u002For repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and\u002For in vitro fertilization (IVF).\n* History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).\n* Eligibility for natural conception attempts and\u002For assisted reproductive technologies according to routine clinical practice.\n* Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis.\n* Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments.\n* Provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding at the time of enrollment.\n* Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).\n* Untreated severe male factor infertility precluding conception by natural or standard ART methods.\n* Active malignancy or history of cancer requiring systemic treatment within the past 5 years.\n* Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician).\n* Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes.\n* Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment.\n* Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.","25 Years",{"count":335,"type":23},15,[68],"The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained infertility. The study also evaluates whether a personalized integrative treatment guided by these biomarkers can improve reproductive outcomes.\n\nThe study includes women aged 25 to 42 years who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated attempts with assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).\n\nThe main questions this study aims to answer are:\n\n* Can telomere and biological aging hallmarks profiling identify a biological aging phenotype associated with infertility?\n* Can an integrative treatment guided by these profiles improve clinical pregnancy outcomes?\n\nParticipants will:\n\n* Undergo a baseline reproductive evaluation and blood-based assessment of telomeres and aging hallmarks.\n* Receive an integrative approach combining Traditional Chinese Medicine (TCM), targeted nutritional support, and standard fertility care.\n* Proceed with natural conception attempts or standard assisted reproductive technologies following the preconception phase.\n* Participants will be followed to assess pregnancy outcomes and changes in biological aging hallmarks.",[339,340,27,71,341],"Idiopathic Infertility","Infertility Unexplained","Infertility Female",[343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366],"Telomere dysfunction","Telomere attrition","Telomere biology","Cellular aging","Mitochondrial dysfunction","Cellular senescence","Reproductive aging","Functional infertility","Idiopathic infertility","Post-treatment unexplained infertility","Oocyte quality","Endometrial receptivity","Biomarkers of reproductive quality","Single-cell FISH","Leukocyte telomere length","Molecular etiology of infertility","Aging hallmarks","Traditional Chinese Medicine","Integrative fertility therapy","Nutraceutical support","Mitochondrial biogenesis","Oxidative stress","Reproductive resilience","Beyond Genomix","2026-04-28",{"date":317,"type":45},{"date":370,"type":45},"2025-01-01",{"date":372,"type":23},"2026-12-01",{"name":374,"class":52},"BEYOND GENOMiX SA, AG, Ltd",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":98,"enrollmentInfo":383,"targetDuration":4,"studyType":66,"phases":385,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100609604","phase-3-human-menopausal-gonadotropin-research-in-infertility-assessing-cumulative-live-birth-with-frozen-embryo-transfer-100609604","NCT07216742","Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.","A Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.","GRACE","Inclusion Criteria:\n\n* Pre-menopausal women aged 18-42 years old at the time of consent.\n* BMI ≥18 and \\\u003C38 kg\u002Fm² at the time of consent.\n* Menstrual cycles between 21-35 days.\n* Normal mammogram or breast ultrasound if patient is \\>40 or if participant is younger as indicated by physician recommendation, within 2 years of screening.\n* Anti-Müllerian hormone (AMH) \\>1.2 ng\u002Fml within 6 months of screening.\n* If donor sperm is used, donor must be 18-40 years of age at the time of collection and compliant with 21 Code of Regulations (CFR) section 1271 Subpart C.\n* Transvaginal ultrasound (TVUS) documenting presence and adequate visualization of both ovaries without ovarian enlargement, normal adnexa, and both ovaries accessible for oocyte retrieval at screening or within 6 months of screening.\n* Valid medical indication for in vitro fertilization (IVF) treatment and subsequent embryo transfer (i.e. history of infertility according to current American Society of Reproductive Medicine (ASRM) definition, single women or same-sex couples) with the intention to achieve pregnancy within 12 months of the first stimulation cycle.\n* Hysterosalpingography, hysteroscopy or saline infusion sonography, documenting a normal uterine cavity (i.e. no müllerian duct anomaly, uterine fibroids, endometrial polyps, intrauterine adhesions, adenomyosis) at screening or within 1 year prior to screening.\n* Normal cervical cytology\u002Fhigh risk human papillomavirus (HPV) testing per American College of Obstetrician\u002FObstetrician Gynecologist (OB\u002FGYN) (ACOG) guidelines.\n* Negative serum hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV) antibody tests at screening.\n* Absence of hydrosalpinx confirmed by hysterosalpingogram (HSG), sonohysterogram, laparoscopy, or other appropriate imaging within the past 12 months.\n* Willing to undergo up to two ovarian stimulation cycles prior to frozen embryo transfer.\n* Willing to self-administer study medications.\n* Willing to have trophectoderm biopsy of all blastocyst stage embryos.\n* Willing to accept transfer of one euploid embryo.\n* Willing to vitrify and warm embryo(s) with intention to have a Frozen Embryo Transfer (FET).\n* Willing and able to comply with the protocol and schedule of events for the duration of the study as well as providing delivery data and neonatal health data.\n\nExclusion Criteria:\n\n* Persistent (for \\>1 cycle), clinically relevant (per PI discretion) ovarian cystic lesion (≥20 mm), including ovarian endometrioma or dermoid cyst.\n* Participants with hepatic impairment (liver function tests \\> 2x upper limit of normal). Participants with renal impairment (estimated creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n* Uncontrolled adrenal, thyroid dysfunction or uncontrolled diabetes (HbA1C \\>7% within 3 months from screening).\n* Greater than one IVF cycle canceled due to inability to meet ovulation trigger criteria (i.e. at least 2-3 follicles reach ≥18 mm.).\n* History of recurrent implantation failure (RIF), defined according to the Lugano Consensus as the absence of implantation after transfer of ≥4 good-quality embryos in ≥3 embryo transfer (ET) cycles in women under the age of 40, using autologous oocytes.\n* Recurrent pregnancy loss (RPL) is defined by two or more miscarriages; that is clinical pregnancies with the same partner and documented by ultrasonography or histopathological examination.\n* Known history of anovulation.\n* Antral Follicle Count (AFC) \\\u003C5 at screening.\n* One or more dominant follicles (≥11 mm) observed on TVUS prior to randomization on stimulation day 1 with evidence of functional activity defined as serum Estradiol level \\>100 pg\u002Fml.\n* Past or current history of an estrogen dependent malignancy\n* Untreated atypical endometrial hyperplasia\n* Any contraindication to the use of oral contraceptives\n* History of OHSS.\n* Morphological sperm evidence of globozoospermia or prior failed oocyte fertilization in previous IVF cycle.\n* The use of donor sperm back up or rescue for fertilization of oocytes.\n* Use of calcium ionophore or treatment of sperm with methyl xanthines.\n* The need for surgically retrieved sperm (i.e. testicular sperm extraction \\[TESE\\], Percutaneous Epididymal Sperm Aspiration \\[PESA\\]).\n* Use of any investigational drug throughout the study, or within 3 months before screening or 5 half-lives whichever is longer.\n* Use of any concomitant medications that would interfere with the study drug and with the evaluation of the study (e.g., hormonal medications or other medications affecting reproductive function), as determined by the investigator, unless permitted by the protocol or meeting required washout criteria.\n* Current use or dependence on psychotropic medications that are contraindicated during pregnancy or have known or suspected fetal risk, unless the Investigator determines that the potential benefit outweighs the risk.\n* Required chronic use of non-steroidal anti-inflammatory drugs during cycle.\n* Treatment with clomiphene citrate, metformin, cabergoline, gonadotropins, or GnRH analogs within 1 month prior to randomization.\n* Pregnancy, lactation, or contraindication to gonadotropins.\n* Known thrombophilia or history of blood clots unless fully evaluated and cleared by a hematologist and receiving appropriate prophylaxis.\n* Known abnormal karyotype in the patient or her partner that is considered clinically significant, such as numerical or structural chromosomal abnormalities (e.g., translocations, inversions, aneuploidies) known to impair fertility, increase risk of miscarriage, or result in genetic disorders in offspring.\n* Current tobacco or marijuana user.\n* Current or past (last 12 months) abuse of alcohol or drugs.\n* Current use of dietary supplements containing high dose of biotin (\\>300µg), if prior use washout period of 1 week prior to randomization.\n* No use of bioidentical hormones during stimulation or up to three months prior to start of stimulation. If prior use: washout period of three months prior to being randomized.\n* A history of chemotherapy or radiotherapy.\n* Undiagnosed uterine bleeding.\n* Tumors of the ovary, breast, adrenal gland, pituitary, or hypothalamus; malformation of sexual organs incompatible with pregnancy.\n* Known active pelvic inflammatory disease.\n* Current, untreated submucosal fibroids or Intramural fibroids ≥5 cm or otherwise clinically relevant pathology that could impair embryo implantation or pregnancy continuation.\n* The presence of severe endometriosis (ASRM stage 3 or stage 4) confirmed by laparoscopy, Magnetic Resonance Imaging (MRI), or pelvic ultrasound.\n* Concomitant participation in another study protocol.\n* Couples identified as carriers of the same autosomal recessive genetic condition associated with serious health outcomes in offspring will be excluded from the trial.\n* Planned use of a gestational carrier.",{"count":384,"type":23},659,[386],"PHASE3","The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.",[27],[390,391,392,393,394],"Controlled ovarian stimulation","Gonadotropins","frozen embryo transfer","cumulative live birth rate","hMG","2026-04-24",{"date":397,"type":45},"2026-04-27",{"date":399,"type":45},"2025-11-01",{"date":401,"type":23},"2028-11",{"name":403,"class":52},"Granata Bio Corporation",16,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":66,"phases":415,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":53},"100623403","standardization-of-variable-conditions-of-embryo-transfer-into-the-uterine-cavity-in-the-procedure-of-medically-assisted-procreation-in-humans-100623403","NCT07396181","Standardization of Variable Conditions of Embryo Transfer Into the Uterine Cavity in the Procedure of Medically Assisted Procreation in Humans","A Randomized, Prospective, Single-center, Controlled, Single-blind Study to Evaluate the Impact of Standardization of Variable Embryo Transfer Conditions in a Medically Assisted Procreation Procedure in Humans on the Effectiveness of the Procedure, by Using: Standardization of Culture Conditions and Selection of Embryo for Transfer Through the Use of an Incubator With a Time-lapse Observation System and AI, an Embryopass-electronically Controlled Device for Controlled ET, and the Embryocase Device Maintaining Optimal Environmental Conditions for the Embryo Outside the Incubator During ET Time","EFECT","Inclusion Criteria:\n\n* The patient and her partner gave written, informed consent to participate in the clinical trial.\n* The patient underwent a medically assisted procreation procedure using IVF or ICSI in accordance with the applicable law, did not have a fresh transfer, has all frozen embryos in the blastocyst stage, of which at least 1 is of good quality\n* You and your partner are not currently taking part in or have not participated in any other clinical trial in the last 6 months.\n* The patient's age on the day of screening ranges from ≥18 to ≤38 years.\n* The patient's BMI on the day of screening ranges from ≥18 to \\\u003C 30.\n* Both partners have normal infectious tests performed 6 months before ET and bacteriological tests performed one month before ET.\n* The patient has had IVF or ICSI embryo culture performed in an incubator with a Time Lapse monitoring system and an Artificial Intelligence system (or if not, the embryo will be placed in the EmbryoScope after thawing) and has not had a fresh transfer (all embryos after stimulation and puncture have been frozen), and after thawing she has at least 1 good quality blastocyst evaluated before freezing by an embryologist as a good quality blastocyst or bl class. 3.2.2. The embryos have also been evaluated by AI prior to freezing and will be thawed in the future in order of the highest AI-confirmed rating.\n* The patient has a normal uterus and endometrium at least 7 mm on ET.\n* The patient must be prepared for cryotransfer in the ovulatory cycle with natural or induced letrozole, and after ovulation in the current cycle, take a progesterone preparation at the doses specified above for luteal phase supplementation.\n* On the day of transfer (5th day after ovulation), the patient must have at least one thawed, developed embryo of good quality - pre-frozen blastocyst 3.2.2 thawed according to the highest AI rating.\n* The patient must be qualified by the doctor for the procedure embryo transfer on day 5 after ovulation.\n* Embryo transfer was performed without general anesthesia or other procedures and\u002For additional antispasmodic drugs prior to transfer (e.g. oxytocin antagonist) with the exception of routine preparation (drotaverine 1 table and 20 mg p.o. per hour prior to transfer).\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria.\n* The patient was found to have abnormalities in the anatomical structure of the uterus and reproductive tract, which, according to the researcher, could reduce the chances of getting pregnant.\n* The patient was diagnosed with endometrial polyp(s).\n* The patient was diagnosed with submucosal or intramural uterine fibroids.\n* The patient was diagnosed with fallopian tube hydromas.\n* The patient was diagnosed with ≥3 endometriosis.\n* The patient or her partner is a carrier of a genetic defect that may have an impact on lowering fertility.\n* The patient or her partner is currently or has been undergoing cancer treatment in the past, which may have had a negative impact on fertility.\n* The patient has had 1 unsuccessful embryo transfer in the past, which means no clinical pregnancy.\n* During the trial transfer in the preceding cycle, difficulties in entering the uterine cavity (the so-called difficult transfer) were found or if the patient had had an embryo transfer in the past and it was described as difficult, even if she became pregnant as a result.\n* Embryos are formed from eggs after PBB (polar body biopsy) of oocytes have been examined or have undergone genetic testing of embryos.\n* The embryos were formed from oocytes after cryopreservation.\n* Semen was obtained for a procedure other than normal ejaculation (retrograde bladder ejaculation, epididymis biopsy, testicular biopsy, M-TESE).\n* The patient did not take progesterone for luteal phase supplementation.\n* Inability to perform embryo transfer on day 5 after ovulation due to medical or random reasons.\n* The patient has indications for general anesthesia or pre-transfer antispasmodic procedure\u002Fmedication (oxytocin receptor antagonist other than Drotaverine, or others that may affect implantation (intralipid, neupogen, and other significant in the investigator's judgment).\n* The patient is to have an incision made in the AH areola before the ET procedure.\n* The patient wants to have Embryoglue used for transfer.\n* The patient takes heparin, Clexane, Acesan, Relanium drugs on and after embryo transfer.","38 Years",{"count":159,"type":23},[68],"The EFECT study is a clinical trial designed to determine whether improving the consistency of embryo transfer procedures can increase pregnancy success in patients undergoing frozen embryo transfer (cryoET). While laboratory techniques for fertilization, embryo culture, and selection have advanced significantly, the process of transferring embryos to the uterus remains variable and depends on small procedural differences, such as temperature changes, mechanical forces, timing, and individual operator techniques. These variations may affect embryo survival and implantation, ultimately influencing pregnancy outcomes.\n\nThis study tests whether using specialized devices to standardize key aspects of embryo transfer-specifically temperature stability during transport and controlled, precise embryo aspiration and expulsion speed, optimal fluid volume, programmed injection time, elimination of pressure fluctuations and plunger backflow, prevention of embryo re-aspiration and detection of transfer catherer oclusion-can improve pregnancy rates. All embryos in the study are cultured using time-lapse monitoring and selected using artificial intelligence-supported grading, ensuring uniform quality for all participants. The study compares standard manual embryo transfer with transfer using one or both of the devices: Embryocase, which maintains a stable temperature during transport, and Embryopass, which standardizes the procedure and eliminates human factor.\n\nA total of 160 participants are randomly assigned to one of four groups: manual transfer without device support, manual transfer with Embryocase, transfer with Embryopass, or transfer with both devices. Participants and outcome assessors are blinded to group assignment, while the staff performing the transfer are aware due to the nature of the devices. All participants receive standard luteal phase support with progesterone following routine clinical practice.\n\nThe study's main goal is to evaluate whether these procedural improvements lead to higher rates of biochemical pregnancy (positive pregnancy test) and clinical pregnancy (confirmed by ultrasound). Secondary outcomes include implantation rate, live birth rate, device safety, and ease of use as reported by staff. Pregnancy outcomes, including delivery, pregnancy loss, or ectopic pregnancy, are followed until the end of pregnancy.\n\nBy investigating the impact of procedural standardization, this study aims to determine whether technological improvements during embryo transfer can increase the effectiveness of assisted reproductive treatments. If successful, the results could support the broader adoption of standardized, device-assisted embryo transfer protocols in fertility clinics, helping more patients achieve successful pregnancies.",[27,32,418],"ART",[420,421,422,423,424,425,426,427,428,429,32],"ET","cryo-ET","AI","Embryopass","Embryocase","embryo transfer","device","standardization","efect","controlled","2026-04-08",{"date":432,"type":45},"2026-04-13",{"date":434,"type":45},"2026-01-01",{"date":436,"type":23},"2027-10",{"name":438,"class":88},"Przychodnia Lekarska nOvum Katarzyna Kozioł, Piotr Lewandowski sp.k.",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":66,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":53},"100573426","phase-3-cleavage-stage-versus-blastocyst-stage-embryo-transfer-in-ivf-patients-with-few-embryos-100573426","NCT06746129","Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos","Day 3 Versus Day 5 Embryo Transfer in IVF Patients With Few Embryos","PRECiSE","Inclusion Criteria:\n\n* autologous IVF cycle\n* ≤5 zygotes on day 1 of development\n* Fresh embryo transfer\n\nExclusion Criteria:\n\n* Planned preimplantation genetic testing (PGT) of all embryos\n* More than 2 previous IVF cycles\n* History of recurrent pregnancy loss (≥3)\n* Body mass index \\>40\n* Presence of uterine factor infertility\n* Planned gestational carrier\n* Endometrial lining \\\u003C6mm measured on the day of trigger\n* Lupron-only trigger, elevated progesterone in the fresh cycle (≥1.5ng\u002Fml)\n* Delayed fertilization (\\>18 hours)\n* Rescue intracytoplasmic sperm injection (following failed regular fertilization)\n* Use of non-ejaculated sperm (testicular sperm extraction)\n* Embryo transfer number outside American Society of Reproductive Medicine (ASRM) guidelines\n* Cycle is converted to a cycle in which all embryos are frozen","44 Years",{"count":449,"type":23},1126,[386],"Infertility affects more than 6 million women the United States and is a major life event that results in a wide range of socio-cultural, emotional, physical and financial problems. The most successful treatment for infertility, in-vitro fertilization (IVF), fertilizes a woman's eggs with her partner's sperm in a culture dish and transfers the resulting embryos into the uterus. Most of the time, prior to being transferred, embryos are grown in the dish for 5-7 days after which some of them reach an advanced stage (blastocyst stage). This has several advantages such as a lower chance of a multiple pregnancies (twins, triplets etc.) after transfer and fewer transfer procedures. However, it is possible that embryos would survive better if transferred into the uterus at the 8-cell stage after growing them for only 3 days. Thus, when patients only have a small number of embryos they and their physicians face the difficult choice when to transfer because there are currently no studies available to guide this decision.\n\nThis randomized controlled trial is comparing pregnancy outcomes and patient satisfaction of poor prognosis patients with 5 or fewer embryos undergoing either transfer of an advanced (blastocyst) or an 8-cell embryo.\n\nThis study will provide the data for the development of guidelines for IVF providers to make evidence-based decisions when to transfer embryos in poor prognosis IVF patients, reduce patients' anxiety regarding cycle cancellation and improve patient counseling, which will increase patients' ability to participate in the development of their treatment plan.",[27],[454,455,456,457,425],"infertility","in vitro fertilization","cleavage stage embryo","blastocyst","2026-03-28",{"date":460,"type":45},"2026-04-02",{"date":462,"type":45},"2025-09-10",{"date":464,"type":23},"2031-06-30",{"name":466,"class":88},"Beth Israel Deaconess Medical Center",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":62,"minAge":97,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":66,"phases":478,"briefSummary":479,"conditions":480,"keywords":485,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":53},"100628395","noninvasive-implantation-potential-vs-morphology-based-selection-in-ivf-single-blastocyst-transfer-100628395","NCT07461077","Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer","Clinical Outcomes of Non-invasive Embryo Implantation Potential Assessment Versus Conventional Morphological Selection for Single Blastocyst Transfer Following Conventional IVF: A Multicenter Randomized Controlled Trial","NICSAI-SBT-RCT","Inclusion Criteria:\n\n1. Conventional IVF insemination;\n2. Meeting either of the following:\n\n   1. Advanced maternal age: female age 35-43 years;\n   2. Recurrent miscarriage: ≥2 spontaneous pregnancy losses (\\\u003C28 gestational weeks), including biochemical pregnancy (hCG \\>25 IU\u002FL) ;\n3. Willingness to culture all Day 3 embryos to the blastocyst stage in the fresh cycle, or to culture ≥6 embryos (with at least one embryo ≥7 cells), and to cryopreserve all blastocysts as single-blastocyst vitrification;\n4. Willingness to undergo frozen-thawed single-blastocyst transfer;\n5. At least two blastocysts formed on Day 5\u002FDay 6 from 2PN fertilization, with morphological grading ≥4BC\u002F4CB;\n6. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Any use of intracytoplasmic sperm injection-based fertilization, including but not limited to ICSI, TESA, and PGT-related cycles;\n2. Known monogenic disorders or chromosomal abnormalities at enrollment;\n3. Patients who use donated eggs to achieve pregnancy;\n4. Definite conditions affecting uterine cavity anatomy or endometrial receptivity, such as untreated uterine malformations (e.g., septate uterus, unicornuate uterus, didelphys uterus) or untreated hydrosalpinx;\n5. Contraindications to pregnancy or to assisted reproductive technology;\n6. Any other condition deemed by the investigators to make the participant unsuitable for this study.","43 Years",{"count":477,"type":23},520,[68],"Background: Morphology-based embryo selection cannot detect aneuploidy, which is common in advanced maternal age and recurrent pregnancy loss. NICS-AI combines non-invasive chromosome screening (NICS) of cell-free DNA from spent blastocyst culture medium with AI integration of developmental day and morphology to improve embryo ranking.\n\nMethods: This multicenter, single-blind, parallel randomized controlled trial will include 520 participants. Participants undergoing conventional IVF will be eligible if they meet either (i) female age 35-43 years or (ii) recurrent miscarriage (≥2 losses \\\u003C28 gestational weeks, including biochemical pregnancy with serum hCG \\>25 IU\u002FL). They must consent to blastocyst culture\u002Fvitrification and frozen-thawed single blastocyst transfer (SBT), and have ≥2 Day-5\u002FDay-6, 2PN-derived blastocysts with morphology grade ≥4BC\u002F4CB at randomization. Key exclusions include any ICSI-based fertilization or PGT-related procedures, known genetic disease meeting PGT indications, donor oocytes, untreated uterine anomalies\u002Fhydrosalpinx, or contraindications to pregnancy\u002FART.\n\nRandomization\u002Finterventions: Participants will be randomized 1:1 to NICS-AI-guided selection or morphology-based selection. In the NICS-AI arm, culture-medium DNA is tested and an AI-derived composite implantation score ranks embryos; controls use morphology alone (tie-break by cryopreservation order).\n\nOutcomes\u002Fanalysis: The primary endpoint is live birth after the first SBT (delivery with ≥1 live-born infant per transfer cycle, per randomized participant). Secondary endpoints include first clinical pregnancy, early miscarriage (\\\u003C12 weeks, excluding biochemical pregnancy), ongoing pregnancy to 12 weeks, and cumulative pregnancy\u002Flive birth outcomes within 1 year (≤3 SBTs from one retrieval). Safety includes fetal malformations and neonatal outcomes through 1 year postpartum.",[481,482,27,483,484],"Advanced Age","Recurrent Pregnancy Loss(RPL)","Sequence Analysis","Embryo Quality",[486,422,487,488,76],"NICS","single embryo transfer","live birth rate","2026-03-04",{"date":491,"type":45},"2026-03-10",{"date":493,"type":23},"2026-04-30",{"date":495,"type":23},"2032-03-31",{"name":497,"class":88},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":62,"minAge":97,"maxAge":98,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":53},"100625935","pilot-study-of-discarded-blastocysts-100625935","NCT07429097","Pilot Study of Discarded Blastocysts","Prospective Observational Pilot Study of Discarded Blastocysts: a Molecular Approach to Uncovering Hidden Reproductive Potential","DECODE","Inclusion Criteria:\n\n* Patients whose written informed consent approved by the Ethic Committee has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits, and any discomfort involved.\n* Patients undergoing regular IVF\u002FICSI cycles with fresh oocytes and embryo culture to the blastocyst stage (day 5-6 after fertilization)\n* Patients' age will be between 20-42 years of age.\n* Patients without PGT-M or PGT-SR indication.\n\nExclusion Criteria:\n\n* Patients who do not have at least one discarded blastocyst on day 5-6 of development.\n* Patients with discarded blastocysts that do not meet these criteria:\n* Presence of ICM\n* Non-degenerated",{"count":507,"type":23},150,"The goal of this observational study is to determine multiomics patterns related to global embryo quality to help overcome the limitations of conventional embryo quality assessment. The main question it aims to answer is:\n\n• Do discarded blastocysts that reach the blastocyst stage (days 5-6) show characteristic multiomics profiles which correlate with chromosomal abnormalities, providing insights into embryo viability?\n\nFor that, patients undergoing an IVF treatment will be asked to donate their clinically discarded 5\u002F6-day embryos (those that do not meet clinical criteria to be used for reproductive purposes). Participation in the study will not interfere with the planned IVF treatment. Patient participation is limited to signature of the informed consent to donate embryos and no other study-specific procedures will be performed on participants.",[27],[457,511,512,29,513],"aneuploidy","inner cell mass","trophectoderm","2026-02-23",{"date":516,"type":45},"2026-02-24",{"date":518,"type":23},"2026-02",{"date":520,"type":23},"2027-05",{"name":51,"class":52},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":529,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":53},"100599644","ai-driven-model-impact-on-patient-engagement-in-medically-assisted-reproduction-100599644","NCT07087171","AI-Driven Model Impact on Patient Engagement in Medically Assisted Reproduction","Assessing the Impact of an Artificial Intelligence-Machine Learning Model on Patient Engagement in Medically Assisted Reproduction","Inclusion Criteria:\n\n* Infertile patients aged 18-45 years\n* Patients willing to undergo Medically Assisted Reproduction (heterosexual couples, same-sex female couples and single females undergoing artificial insemination, IVF\u002FICSI or oocyte donation treatments)\n\nExclusion Criteria:\n\n* Age \\>45 years\n* Patients who are not candidates for IVF\u002FICSI\n* Patients who are menopausal or peri-menopausal\n* Patients undergoing Fertility Preservation\n* Same-sex couples who will undergo reception of oocytes from partner.\n* Patients who decline to be counselled about their probability of having a live birth from IVF\u002FICSI treatment",{"count":530,"type":23},774,"Infertility is a globally significant medical condition, profoundly impacting individuals and couples both emotionally and physically. The multifaceted nature of in vitro fertilization (IVF) treatment demands active patient participation, with engagement playing a pivotal role in treatment success and satisfaction. However, suboptimal engagement can lead to challenges such as not initiating treatment, missed appointments, medication errors, dropping out and heightened stress levels, all of which may adversely affect clinical outcomes.\n\nRecent advancements in Artificial Intelligence (AI) and Machine Learning (ML) have revolutionized healthcare, offering innovative solutions for personalized patient care. In IVF, AI-ML models hold the potential to enhance patient engagement by delivering tailored communication, reminders, and educational support, but also improved prognostication by providing personalized and accurate predictions of treatment outcomes. These capabilities enable patients to make more informed decisions and enhance their adherence to treatment protocols.This protocol outlines a prospective evaluation of an AI-ML model, specifically the Univfy PreIVF report, developed to improve patient engagement in IVF care. Recently, a retrospective, multicenter study reported improved IVF utilization rates among patients counselled using the Univfy PreIVF Report. The current study will prospectively assess the model's effectiveness in addressing individual patient needs and creating a supportive treatment environment. Specifically, this study will measure adherence to providers' recommendation of treatment protocols. By analyzing the impact of these interventions, this research aims to provide robust evidence for the integration of AI-ML technologies in reproductive medicine, paving the way for broader implementation and improved patient outcomes.",[27,533],"Artificial Intelligence (AI)",[535,536,537,538],"IVF","Artificial intelligence","counselling","Conversion rate","2026-02-20",{"date":514,"type":45},{"date":542,"type":45},"2025-06-11",{"date":146,"type":23},{"name":545,"class":546},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":62,"minAge":97,"maxAge":259,"enrollmentInfo":553,"targetDuration":4,"studyType":66,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":53},"100624427","ivf-outcomes-with-time-lapse-culture-comparison-between-ppos-and-gnrh-antagonist-protocols-100624427","NCT07409493","IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols","Inclusion Criteria:\n\n* Women aged 20-45 years\n* Indicated for in vitro fertilization (IVF) treatment\n* Planned freeze-all embryo strategy\n* Voluntary participation in research.\n\nExclusion Criteria:\n\n* Systemic diseases\n* Use of hormonal medications within 3 months prior to enrollment\n* Oocyte donation cycles\n* Unwilling or unable to participate in research",{"count":554,"type":23},148,[68],"The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol. The study will evaluate IVF outcomes and embryo development patterns using time-lapse embryo monitoring technology. The main questions the study aims to answer are:\n\n* Does the fixed - PPOS protocol achieve similar numbers of mature eggs, good-quality embryos, and clinical outcomes compared to the GnRH Antagonist protocol?\n* Are there differences in embryo development patterns (morphokinetics) between the two protocols when monitored by time-lapse imaging?\n* How does embryo quality (KIDScore) compare between the two protocols?\n\nStudy Design:\n\nResearchers will randomly assign 148 women undergoing IVF to two groups:\n\n* PPOS group (n=74): Will receive FSH injections (oral Duphaston 20mg daily) starting from day 2-3 of the menstrual cycle\n* GnRH Antagonist group (n=74): Will receive FSH injections (Orgalutran 0.25mg injections) when follicles reach ≥14mm\n\nParticipants will:\n\n* Undergo controlled ovarian stimulation with their assigned protocol for approximately 10-12 days\n* Have regular ultrasound monitoring and blood tests to track follicle development\n* Undergo egg retrieval procedure when follicles are mature\n* Have all embryos cultured in the EmbryoScope time-lapse incubator with continuous monitoring\n* Have embryos frozen on Day 5\u002F6 for future transfer\n\nStudy Location:\n\nDepartment of Assisted Reproduction and Andrology, Hanoi Obstetrics and Gynecology Hospital\n\nStudy Duration: January 2026 - June 2028",[27,558,559],"Embryo Morphokinetics","Progestins Primed Ovarian Stimulation",[535,74,561],"Embryo morphokinetics","2026-02-12",{"date":564,"type":45},"2026-02-13",{"date":566,"type":45},"2026-01-21",{"date":568,"type":23},"2028-10",{"name":570,"class":88},"Hanoi Medical University",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":66,"phases":581,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":598},"100618699","the-role-of-follicular-flushing-at-oocyte-retrieval-100618699","NCT07335016","The Role of Follicular Flushing at Oocyte Retrieval","FOFLOR","Inclusion Criteria:\n\n* Ovarian stimulation with recFSH and GnRH antagonist or PPOS protocol\n* Triggering final oocyte maturation with hCG or GnRH agonist\n* The day of oocyte retrieval at least one follicle of mean diameter of 11mm in each ovary\n* ICSI method of fertilisation.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst of endometriosis\n* History of ovarian surgery\n* Monofollicular growth\n* Presence of only one ovary\n* Ovary not accessible at oocyte retrieval","46 Years",{"count":580,"type":23},75,[68],"In vitro fertilization (IVF) is the most common method of medically assisted reproduction, involving fertilization of the egg by sperm in a lab. The process includes ovarian stimulation, oocyte retrieval, fertilization and culture, and embryo transfer. The success of IVF depends mainly on female age-as age increases, ovarian reserve and oocyte quality decrease-and the number of oocytes retrieved.\n\nThis study investigates whether follicular flushing during oocyte retrieval can increase the number of mature oocytes retrieved. This randomized study will be conducted in women undergoing ovarian stimulation with recombinant Folicullar Stimulating Hormone (FSH) and Gonadotropin-Releasing Hormone (GnRH) antagonist or Progestin Primed Ovarian Stimulation (PPOS) to suppress premature Luteinizing hormone (LH) rise. Final oocyte maturation will be triggered with recombinant Human chorionic gonadotropin (hCG) or GnRH agonist.\n\nEligible participants will have at least one follicle ≥11 mm in each ovary. On the day of oocyte retrieval, one ovary will be randomized to undergo follicular flushing using a single-lumen needle and the other simple aspiration, using the same needle. All fertilized oocytes from both ovaries will be cultured, seperately, to the blastocyst stage.\n\nStudy outcomes are the number of oocytes and mature oocytes retrieved, the oocyte retrieval rate, the mature oocyte retrieval rate, the maturation rate, the number of fertilized oocytes, the fertilisation rate, the number of blastocytes and the blastulation rate.\n\nSample size of 75 patients (25 per response category: poor, normal, high) provides 82-98% power to detect clinically meaningful interaction effects (Cohen's f=0.19-0.34) between response category and technique (follicular flushing vs. simple aspiration) under conservative assumptions of 50-70% of pilot study effects, lower correlations (ρ=0.35), and increased variability (α=0.05, two-sided, 5% attrition buffer.",[27,584],"Oocyte Retrieval for IVF",[586,587,588],"ivf","follicular flushing","oocyte retrieval","2026-01-11",{"date":591,"type":45},"2026-01-13",{"date":593,"type":23},"2026-01-14",{"date":595,"type":23},"2029-01-20",{"name":597,"class":88},"Aristotle University Of Thessaloniki",2,{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":66,"phases":609,"briefSummary":610,"conditions":611,"keywords":612,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":53},"100617800","phase-2-growth-hormone-and-dehydroepiandrosterone-role-in-vitro-fertilization-100617800","NCT07323329","Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization","Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization","Inclusion Criteria:\n\nAt least two of the following three criteria had to be present after maximal stimulation:\n\n1. Advanced maternal age (\\>40 years) or any other risk factor for Poor Ovarian Response (POR).\n2. ≤3 oocytes with a conventional stimulation protocol).\n3. An abnormal ovarian reserve test \\[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng\u002Fml\\].\n\nExclusion Criteria:\n\n1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.\n2. Any pelvic pathology such as hydrosalpinx, uterine anomaly.\n3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia","35 Years",{"count":608,"type":23},165,[131,386],"The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.\n\nThe main question it aims to answer is:\n\nWhich intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.",[32,27],[613,32,614,615],"Growth hormone","IVF patients","Ovarian reserve","2025-12-31",{"date":618,"type":45},"2026-01-07",{"date":620,"type":45},"2025-10-10",{"date":622,"type":23},"2026-11-12",{"name":624,"class":88},"Beni-Suef University",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":632,"enrollmentInfo":633,"targetDuration":4,"studyType":66,"phases":634,"briefSummary":636,"conditions":637,"keywords":642,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":53},"100607220","phase-4-ketorolac-use-and-fresh-embryo-transfer-outcomes-100607220","NCT07185724","Ketorolac Use and Fresh Embryo Transfer Outcomes","Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers","Inclusion Criteria:\n\n* IVF utilizing autologous oocytes and all sperm sources\n* IVF cycles utilizing ICSI and standard insemination\n* Plan to transfer embryo on day 5\n* BMI below 50\n\nExclusion Criteria:\n\n-allergies or medical contraindications to NSAIDs","37 Years",{"count":159,"type":23},[635],"PHASE4","Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy.\n\nHowever, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle).\n\nDespite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research.\n\nThis study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would.\n\nPrimary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia.\n\nSecondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w\u002Fin 24 hours for pain\u002Fbleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.",[27,638,639,640,641],"Infertility Treatment","Post-op Pain","Fresh Embryo Transfer","Oocyte Retrieval and Post Operative Pain Control",[535,643,588,644,645,646,647,488,648],"post operative pain control","fresh embryo transfer","ketorolac","toradol","implantation rate","miscarriage rate","2025-12-11",{"date":651,"type":45},"2025-12-15",{"date":653,"type":45},"2025-11-08",{"date":655,"type":23},"2028-09-01",{"name":657,"class":88},"Jessica D. Kresowik",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":157,"sex":62,"minAge":97,"maxAge":665,"enrollmentInfo":666,"targetDuration":4,"studyType":66,"phases":667,"briefSummary":668,"conditions":669,"keywords":670,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":676,"leadSponsor":678,"locationsCount":598},"100604398","phase-1-an-advanced-decision-support-tool-for-personalized-medicine-for-ivf-using-modeling-and-optimization-for-provera-100604398","NCT07148999","An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera","An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for PPOS","Inclusion Criteria:\n\n* infertile women\n\nExclusion Criteria:\n\nAll female patients who will not undergo IVF or whose cycles will be converted to IUI. Male patients will not be enrolled in this study. No donor cycles.","50 Years",{"count":159,"type":23},[130,131],"A clinical trial will determine the effectiveness of using the Opt-IVF decision support tool for each patient's personalized and optimal drug dosage profile in the United States.",[27],[671],"Opt-IVF","2025-09-23",{"date":674,"type":45},"2025-09-29",{"date":672,"type":23},{"date":677,"type":23},"2026-02-15",{"name":679,"class":52},"Urmila DIwekar",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":684,"acronym":4,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":237,"minAge":19,"maxAge":665,"enrollmentInfo":686,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":687,"conditions":688,"keywords":690,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":700,"locationsCount":53},"100607240","functional-development-and-clinical-validation-of-a-diagnostic-tool-based-on-artificial-intelligence-for-the-assessment-of-sperm-quality-and-the-selection-of-the-optimal-in-vitro-fertilisation-ivf-treatment-100607240","NCT07185984","Functional Development and Clinical Validation of a Diagnostic Tool Based on Artificial Intelligence for the Assessment of Sperm Quality and the Selection of the Optimal In Vitro Fertilisation (IVF) Treatment","* Inclusion criteria:\n\n  * Men between the ages of 18 and 50 who come to the clinic to undergo an ICSI cycle.\n  * Men between the ages of 18 and 50 who come to the clinic to undergo an artificial insemination cycle.\n  * All embryos will be placed in a time-lapse incubator.\n  * All women over 18 years of age who have obtained a MII number greater than or equal to 2 in oocyte retrieval, without excluding couples from the oocyte donation programme.\n  * All men and women with a previously known normal karyotype.\n  * Informed consent (IC) provided and signed by patients.\n* Exclusion criteria:\n\n  * All women diagnosed with recurrent pregnancy loss.\n  * All semen samples obtained by testicular biopsy.\n  * All donor semen samples.",{"count":159,"type":23},"Infertility is a growing global health problem affecting millions of couples worldwide, with male infertility accounting for approximately half of all cases. In the physiological environment, sperm go through an exhaustive selection process in the female reproductive tract before reaching the oocyte. During this journey, progressive mobility and morphology are key parameters for achieving fertilisation. Therefore, before starting an assisted reproduction treatment, it is essential to analyse and process the semen sample to assess the fertile potential, select the most optimal sperm and determine the most appropriate treatment.\n\nConventional methods of semen processing, such as density gradient centrifugation (DGC) and Swim-up washing of motile sperm, have significant limitations. These include interobserver and interlaboratory subjectivity, as well as damage to sperm DNA caused by centrifugation. Alternatively, microfluidics, which simulates natural selection, allows higher counts of morphologically normal, progressive motile sperm to be obtained. On the other hand, the CASA (computer-assisted sperm analysis) system has improved the standardisation and quality of semen analysis. Furthermore, the incorporation of Artificial Intelligence (AI) into semen quality analysis represents a promising opportunity, as it improves efficiency, accuracy and standardisation, and has the potential to increase success rates in assisted reproduction treatments.\n\nThis project aims to develop an innovative AI-based diagnostic tool to address male infertility. The tool will integrate microfluidic technology and the CASA system to analyse semen quality, calculate fertilisation potential and recommend personalised treatments with an estimate of success. Trained with large volumes of biological and clinical data, it will provide a comprehensive and patient-specific diagnosis by identifying complex relationships between multiple variables. Finally, a comparative study will be conducted to evaluate laboratory indicators and clinical outcomes of cycles using this tool versus those using conventional methods.",[27,689,286],"Male Fertility",[691,692,536,693],"Male infertility","Microfluidics","Sperm quality","2025-09-19",{"date":696,"type":45},"2025-09-22",{"date":698,"type":23},"2025-11",{"date":148,"type":23},{"name":701,"class":88},"Instituto Valenciano de Infertilidad, IVI VALENCIA",{"id":703,"slug":704,"hasResults":12,"nctId":705,"briefTitle":706,"officialTitle":707,"acronym":4,"eligibilityCriteria":708,"healthyVolunteers":12,"sex":62,"minAge":19,"maxAge":307,"enrollmentInfo":709,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":711,"conditions":712,"keywords":713,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":53},"100571250","endometrial-receptivity-prediction-during-in-vitro-fertilization-using-artificial-intelligence-100571250","NCT06717802","Endometrial Receptivity Prediction During in Vitro Fertilization Using Artificial Intelligence","Endometrial Receptivity Prediction During in Vitro Fertilization Using Artificial Intelligence Analysis of Vaginal Ultrasound Images","Inclusion Criteria:\n\n* Female patient 18-40 years, for whom IVF is indicated\n* Maximum 3 unsuccessful previous embryo transfers\n* Only cycles in which single blastocyst is transferred\n\nExclusion Criteria:\n\n* Congenital uterine anomalies, fibroids, adenomyosis, Asherman-syndrome or any other conditions resulting in malformation of the uterus\n* Presence of hydrosalpinx\n* Endometriosis\n* Planned freeze-all cycle\n* Positive hepatitis B, hepatitis C or HIV screening test",{"count":710,"type":23},1500,"The investigators plan to use artificial intelligence to analyse vaginal ultrasound images of the uterine lining (endometrium) taken during routine IVF treatment, which may predict implantation success during IVF treatment.\n\nParticipation in the study is voluntary, involves no additional testing or intervention beyond routine procedures, and consent can be withdrawn verbally or in writing at any time without cause or adverse consequences.\n\nOver a three-year period, the trial is expected to enrol approximately 1,500 patients between the ages of 18 and 40 who are indicated for IVF treatment and who volunteer for treatment.\n\nPatients enrolled in the study will not be required to attend more clinic visits during treatment than they would otherwise have to. During the trial, certain patient-specific data (age, indication for treatment, body mass index), stimulation-specific data (duration of stimulation, type and dose of drug, endometrial thickness), ultrasound scans and outcome-specific data (treatment failure, biochemical pregnancy, clinical pregnancy) will be collected. The data will be stored in a secure database. The data collected during the study will only be accessible to the professionals involved in the study and no information, including personal data, will be disclosed to third parties.",[32,27],[714,715,354,716,717],"assisted reproduction","Artificial intelligence (AI)","Embryo implantation","Ultrasound imaging",{"date":719,"type":45},"2025-09-11",{"date":721,"type":45},"2025-06-01",{"date":723,"type":23},"2028-12-31",{"name":725,"class":88},"Gottsegen National Cardiovascular Institute"]